Immunological monitoring and biomarkers

Craig Fenwick

Dr Craig Fenwick

Directeur de la plateforme
Responsable de recherche
+41 21 314 1164
Contact email

Team

Michael MOULIN

Research associate
Manon GEISERResearch associate
Flurin FISCALINIResearch associate

Research Focus

The immune-monitoring platform, developed by Dr. Craig Fenwick and Professor Giuseppe Pantaleo, has as its principal goals to identify the immunological profiles associated with different infectious agents, disease states, cancers, and induced by registered and experimental vaccines. Profiling consists of phenotypic identification, characterization of cellular activation states, cell fate evaluation, functionality, phosphosignaling and transcriptomic characterization of immune cells and tissues. The platform achieves its goals through the implementation of established and emerging analysis technologies for phenotypic, functional and genetic characterization of immune cells and through quantitative analysis of serum cytokine and chemokine levels as markers of inflammation, infection and disease.

Technologies implemented include CyTOF mass cytometry, for in depth characterization of cellular phenotype and function with over 45 difference cellular markers evaluated simultaneously, flow cytometry for phenotypic and functional profiling of live cells, cell sorting for the isolation of specific cell populations and gene expression analysis at the single cell levels using Seq-Well gene expression analysis. The immune-monitoring platform has developed highly validated antibody panels for characterizing immune cells from patients at the hospital including those with suspected immunodeficiencies or those undergoing cancer therapy. Specialized antibody panels were also designed to support valuable research studies to investigate immunological implications of specific diseases, identify related cellular biomarkers and identify the cellular targets and mechanism of action associated with specific vaccines and therapies.

Current and recently completed projects Covers

  1. The identification of cytokines HGF and CXCL13 as predict markers of the severity and the mortality in COVID-19 patients.
  2. In depth longitudinal analysis of SARS-CoV-2 Spike and Nucleocapsid specific B cells was also performed with cohorts of patents and donors that were vaccinated and/or mounted a SARS-CoV-2 specific immune response following natural infection.
  3. Phosphosignaling studies to characterize tumour specific T cell responses and BCG vaccine induced long-term functional reprogramming of human neutrophils.
  4. Mass cytometry for the phenotypic characterization of the HIV latently infected cellular reservoirs.
  5. Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE.
  6. High-dimensional immune phenotyping of blood cells by mass cytometry in patients that received a novel HIV vaccine or infected with hepatitis C virus.
  7. Signatures of B cell dysfunction in common variable immunodeficiency patients.
  8. Early antiviral responses in monocytes and dendritic cells are associated with persistent humoral immunity to pertussis following Tdap-IPV vaccination.
  9. SLAMF receptor expression identifies an immune signature that characterizes systemic lupus erythematosus.
  10. Immunological profiling of multiple sclerosis patients treated with ocrelizumab.
  11. Evaluation of activation induced markers following Bordetella pertussis antigen specific stimulation of CD4 T cells in a longitudinal study following boost.
  12. Interdisciplinary study to identify robust biomarkers to predict clinical benefits and immune-mediated adverse events with immune checkpoint (BIOMARK).
  13. Longitudinal and in depth phenotypic characterization of CART cells following administration to cancer patients.
  14. Immunological profiling of Crohn’s disease patients.
  15. Mass cytometry evaluation of bone marrow myeloid cells from immune deficient donors.
  16. Longitudinal study for the identification of immunological signatures associated with rejection and graft outcome after kidney transplantation.
  17. Study of T, B and dendritic immune cell populations in lymph nodes of viremic HIV infected donors, antiretroviral treated HIV infected donors and healthy donors evaluated by mass cytometry and Seq-Well single cell gene expression analysis.
     

International collaborations

Prof. Yves LEVYDirector of the Vaccine Research Institute, Paris, France
Dr. Christine LACABARATZ

Head of Immunomonitoring Platform of the VRI, Paris, France

Prof. Rodolphe THIEBAUT

University of Bordeaux, Bordeaux, France.
Prof. Dimitri DIAVATOPOULOSResearch Institute Radboud Institute for Molecular Sciences, Netherlands
Prof. Cecile VAN ELSRIVM Centre for Immunology of Infectious Diseases and Vaccines, Netherlands
Dr. Laetitia MOINOT

Project Leader at INSERM, Bordeaux, France

Selected Publications

 Dernière mise à jour le 05/08/2022 à 16:04